U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H24N2O4S.ClH
Molecular Weight 364.888
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIAPRIDE HYDROCHLORIDE

SMILES

Cl.CCN(CC)CCNC(=O)C1=C(OC)C=CC(=C1)S(C)(=O)=O

InChI

InChIKey=OTFDPNXIVHBTKW-UHFFFAOYSA-N
InChI=1S/C15H24N2O4S.ClH/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3;/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18);1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H24N2O4S
Molecular Weight 328.427
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11520476

Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly. A derivative of benzamide, tiapride is chemically and functionally similar to other benzamide antipsychotics such as sulpiride and amisulpride known for their dopamine antagonist effects. Tiapride is marketed under various trade names and is widely available outside of the United States. The most common trade name for tiapride is Tiapridal, which is used throughout Europe, Russia, as well as parts of South America, the Middle East, and North Africa. It is also sold under different names in Italy (Italprid, Sereprile), Japan (Tialaread, Tiaryl, Tiaprim, Tiaprizal), Chile (Sereprid), Germany (Tiaprid, Tiapridex), and China (Tiapride).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
45.8 µM [IC50]
Target ID: 1.01906672E8
Gene Symbol: DRD4
11.7 µM [IC50]
180.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Tiacob

Approved Use

For the treatment of neuroleptic-induced tardive dyskinesia, mainly oro-bucco-lingual type.

Launch Date

1.12008954E12
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazole. A pilot study.
2001 Aug
Coadministration of L-NOARG and tiapride: effects on catalepsy in male mice.
2002 Jan
A combination of carbamazepine/tiapride in outpatient alcohol detoxification. Results from an open clinical study.
2002 Oct
Influence of tiapride on platelet counts in healthy volunteers and patients with movement disorders.
2003 Jun
A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients.
2005 Feb
Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia.
2006 Jan 25
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].
2006 Jul 15
Comparison of two pre-exposure treatment regimens in acute organophosphate (paraoxon) poisoning in rats: tiapride vs. pyridostigmine.
2007 Mar
A thyrotoxicosis outbreak due to dietary pills in Paris.
2008 Dec
Voluntary motor drive: possible reduction in Tourette syndrome.
2008 Jun
Patents

Sample Use Guides

Adults should take 100 – 200 mg tiapride three times daily, depending on the severity of the disease and the body weight of the individual . The proposed daily dose for the claimed indication is 300 – 600 mg tiapride. The effect of treatment may not be apparent until after a period of 4-6 weeks of treatment. Tiapride tablets should preferably be taken with a little liquid after meals.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Effects of tiapride on hERG channels expressed in Xenopus oocytes and also on delayed rectifier K(+) currents in guinea pig cardiomyocytes were studied.
Tiapride increased the potential for half-maximal activation (V(1/2)) of HERG at 10~300 uM. In guinea pig ventricular myocytes, bath applications of 100 and 500 uM tiapride at 36℃ blocked rapidly activating delayed rectifier K(+) current (I(Kr)) by 40.3% and 70.0%, respectively.
Substance Class Chemical
Created
by admin
on Thu Jul 06 02:31:30 UTC 2023
Edited
by admin
on Thu Jul 06 02:31:30 UTC 2023
Record UNII
25N106WEDO
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIAPRIDE HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
SEREPRILE
Brand Name English
TIAPRIDE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
ITALPRID
Brand Name English
LUXOBEN
Brand Name English
BENZAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-2-METHOXY-5-(METHYLSULFONYL)-, MONOHYDROCHLORIDE
Common Name English
TIAPRIDAL
Brand Name English
BENZAMIDE, N-(2-(DIETHYLAMINO)ETHYL)-2-METHOXY-5-(METHYLSULFONYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
TIAPRIDE HYDROCHLORIDE [MART.]
Common Name English
TIAPRIDE HCL
Common Name English
TIAPRIDEX
Brand Name English
TIAPRIDE HYDROCHLORIDE [JAN]
Common Name English
GRAMALIL
Brand Name English
TIAPRIDE HYDROCHLORIDE [MI]
Common Name English
Tiapride hydrochloride [WHO-DD]
Common Name English
Code System Code Type Description
ECHA (EC/EINECS)
256-908-4
Created by admin on Thu Jul 06 02:31:30 UTC 2023 , Edited by admin on Thu Jul 06 02:31:30 UTC 2023
PRIMARY
ChEMBL
CHEMBL84158
Created by admin on Thu Jul 06 02:31:30 UTC 2023 , Edited by admin on Thu Jul 06 02:31:30 UTC 2023
PRIMARY
EPA CompTox
DTXSID4045210
Created by admin on Thu Jul 06 02:31:30 UTC 2023 , Edited by admin on Thu Jul 06 02:31:30 UTC 2023
PRIMARY
FDA UNII
25N106WEDO
Created by admin on Thu Jul 06 02:31:30 UTC 2023 , Edited by admin on Thu Jul 06 02:31:30 UTC 2023
PRIMARY
SMS_ID
100000091110
Created by admin on Thu Jul 06 02:31:30 UTC 2023 , Edited by admin on Thu Jul 06 02:31:30 UTC 2023
PRIMARY
PUBCHEM
39855
Created by admin on Thu Jul 06 02:31:30 UTC 2023 , Edited by admin on Thu Jul 06 02:31:30 UTC 2023
PRIMARY
CAS
51012-33-0
Created by admin on Thu Jul 06 02:31:30 UTC 2023 , Edited by admin on Thu Jul 06 02:31:30 UTC 2023
PRIMARY
MERCK INDEX
M10846
Created by admin on Thu Jul 06 02:31:30 UTC 2023 , Edited by admin on Thu Jul 06 02:31:30 UTC 2023
PRIMARY Merck Index
EVMPD
SUB04854MIG
Created by admin on Thu Jul 06 02:31:30 UTC 2023 , Edited by admin on Thu Jul 06 02:31:30 UTC 2023
PRIMARY
DRUG BANK
DBSALT002373
Created by admin on Thu Jul 06 02:31:30 UTC 2023 , Edited by admin on Thu Jul 06 02:31:30 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY